Twist Bioscience, Seismic Bio partner to discover bispecific antibodies
Twist Bioscience and Seismic Bio have formed a partnership to discover and optimize antibodies to high-value immuno-oncology targets. Read More
NIH leads adaptive phase II clinical trial for COVID-19 mAb
The National Institutes of Health (NIH) is now studying an investigational monoclonal antibody (mAb), Ly-CoV555, as part of an adaptive phase II clinical trial. Read More
NIH launches clinical trial for COVID-19 antibody treatment
The National Institutes of Health (NIH) has started enrolling volunteers in a phase III randomized, controlled clinical trial to test multiple monoclonal antibody treatments for COVID-19 patients. Read More
Sciex, 908 Devices launch biotherapeutics characterization platform
Sciex and 908 Devices have made the ZipChip platform for Sciex mass spectrometers available to the public. This platform expands mass spectrometers from end separation solutions for large and small molecule characterization. Read More
Lilly begins phase III trial of COVID-19 antibody treatment
Eli Lilly has begun a phase III trial of its lead COVID-19 antibody treatment candidate, Ly-CoV555. Read More
R&D Alliance begin I-Spy COVID trial
A collaborative research effort that includes the U.S. government and leading pharmaceutical companies has launched a clinical trial to investigate a series of therapeutics to treat patients who are severely ill with the novel coronavirus disease. Read More
NanoString launches readout technology for NGS
NanoString Technologies has released Cancer Transcriptome Atlas, a new product based on the company's GeoMx digital spatial profiler platform that's optimized for readout on Illumina's next-generation sequencing (NGS) technology. Read More
Bio-Techne, Kantaro launch COVID-19 serology test
Bio-Techne and Kantaro Biosciences have launched COVID-SeroIndex, a quantitative SARS-CoV-2 immunoglobulin G antibody research-use only kit. Read More
Neutrolis develops new COVID-19 treatment
Neutrolis has developed a new class of COVID-19 therapy, a DNASEIL3 enzyme analog that has the potential to clear neutrophil extracellular traps for severe cases of COVID-19. Read More
Bio-Rad's Q2 revenue drops
Bio-Rad Laboratories reported that the COVID-19 pandemic negatively impacted its revenue for the second quarter as well as for the first half of the year. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
